VEEV

VEEV's strong Q1, growing Vault CRM migrations and AI expansion support growth, though life sciences CRM market saturation poses risks.

The latest trading day saw Veeva Systems (VEEV) settling at $193.09, representing a -1.89% change from its previous close.

Recently, Zacks.com users have been paying close attention to Veeva (VEEV). This makes it worthwhile to examine what the stock has in store.

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

Veeva (VEEV) reported earnings 30 days ago. What's next for the stock?

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

VEEV expands its AI push with Copli acquisition and Falcon MLR launch, aiming to speed life sciences content reviews and boost Commercial Cloud.

VEEV's Veeva EHS expands Quality Cloud with automated risk, compliance and safety workflows, aiming to replace legacy systems with a unified platform.

Veeva Systems trades at 17x FY2027 earnings, offering high margins and recurring revenue, yet faces slowing Commercial CRM growth and strong competition. R&D and Quality segments now outpace Commercial, growing 19% in Q1 FY2027 and becoming the largest revenue driver, deeply embedded in regulated customer processes. VEEV's moat is strong due to switching costs and integrated solutions, but not unassailable—Salesforce, Oracle, and others remain credible threats.

Veeva (VEEV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.